title: Association of IL28B Genotypes and Baseline Serum Interferon-γ-Inducible- Protein-10 Levels with Treatment Response in Hepatitis C Virus Patients in China.
abstract: OBJECTIVE
  Several studies have demonstrated that serum interferon-γ-inducible-protein-10 (IP-10) levels at baseline and single nucleotide polymorphisms (SNPs) near the IL28B gene were associated with viral response and treatment outcomes. Our purpose was to assess the combination of pretreatment IP-10 levels with IL28B SNPs as predictors of treatment response to pegylated interferon α-2a plus ribavirin in patients infected with genotype 1 hepatitis C virus in China.
  
  
  METHODS
  Seventy-two patients with chronic hepatitis C without fibrosis/cirrhosis were enrolled in the study. The virologic parameters and baseline serum IP-10 levels were determined. IL-28B genotypes were determined by sequencing.
  
  
  RESULTS
  In this cohort, serum baseline IP-10 levels lower than 426.7 pg/mL could predict rapid virological response/ sustained virological response (SVR). Patients carrying favorable IL28B SNP genotypes had higher SVRs than did those carrying unfavorable variants (IL28B rs12979860, p=0.002; IL28B rs8099917, p=0.020). Combining both baseline IP- 10 and IL28B SNPs could improve the prediction of SVR in favorable allele carriers of IL28B, rs12979860 CC and rs8099917 TT. Serum baseline IP-10 levels and IL28B genotypes were independent predictors of SVR.
  
  
  CONCLUSIONS
  Our study shows that the combination of baseline serum IP-10 levels and the determination of IL28B SNPs increase the predictability of SVR rates in this cohort. (Gut Liver 2016;10446-455).
authors.affiliation: Department of Infectious Diseases, Peking University First Hospital, Beijing, China.
authors.forename: Renwen
authors.initials: R
authors.lastname: Zhang
authors.affiliation: Department of Infectious Diseases, Peking University First Hospital, Beijing, China.
authors.forename: Cuiping
authors.initials: C
authors.lastname: Shao
authors.affiliation: Department of Infectious Diseases, Peking University First Hospital, Beijing, China.
authors.forename: Na
authors.initials: N
authors.lastname: Huo
authors.affiliation: Department of Infectious Diseases, Peking University First Hospital, Beijing, China.
authors.forename: Minran
authors.initials: M
authors.lastname: Li
authors.affiliation: Department of Infectious Diseases, Peking University First Hospital, Beijing, China.
authors.forename: Xiaoyuan
authors.initials: X
authors.lastname: Xu
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use; D054357:Chemokine CXCL10 / Q000378:metabolism*; D004359:Drug Therapy, Combination; D005260:Female; D005838:Genotype; D019698:Hepatitis C, Chronic / Q000097:blood / Q000188:drug therapy / Q000235:genetics*; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use; D007372:Interferons; D007378:Interleukins / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000627:therapeutic use; D020641:Polymorphism, Single Nucleotide / Q000235:genetics*; D012372:ROC Curve; D011994:Recombinant Proteins / Q000627:therapeutic use; D012254:Ribavirin / Q000627:therapeutic use; D016896:Treatment Outcome; D000095022:Interferon Lambda
chemical_list: D000998:Antiviral Agents; D054357:Chemokine CXCL10; D016898:Interferon-alpha; D007372:Interferons; D007378:Interleukins; D011092:Polyethylene Glycols; D011994:Recombinant Proteins; D012254:Ribavirin; C114753:CXCL10 protein, human; C000624353:interferon-lambda, human; D000095022:Interferon Lambda; C100416:peginterferon alfa-2a
keywords: -2a plus ribavirin; -inducible-protein-10; IL28B; Interferon-γ; Pegylated interferon α; Viral response